Belumosudil for Long‐Standing Refractory Chronic Graft‐Versus‐Host Disease: A Two‐Patient Case Report

ABSTRACT

In long‐standing fibrotic chronic GVHD refractory to multiple systemic therapies, belumosudil may provide clinically meaningful patient‐reported improvement and reduce infection‐related hospitalizations even when early NIH organ scores remain stable. When benefits are evident and safety is acceptable, continuation beyond 3–6 months may be reasonable.